Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial
Status:
Recruiting
Trial end date:
2022-05-18
Target enrollment:
Participant gender:
Summary
This study is an adaptive, randomized, open-label, controlled clinical trial, in
collaboration with countries around the world through the World Health Organization.
Subjects will be randomized to receive either standard-of-care products or the study
medication plus supportive care, while being hospitalized for COVID-19.
Participants will be randomized to one of the following groups:
1. Remdesivir 200mg IV on day 1, followed by 100 mg IV daily infusion for 9 days plus
optimized supportive care, OR
2. Interferon-beta-1a, 22 or 44 micrograms subcutaneously on days 1, 3 and 6, plus
optimized supportive care OR
3. Optimized support care, all or until discharge from hospital, whichever occurs first